TNF-α inhibitors, including etanercept and adalimumab, have proven effective in a wide range of autoimmune diseases—psoriatic arthritis (217, 218), psoriasis (219), RA (218, 220), ulcerative colitis (221, 222), Crohn’s disease, and ankylosing spondylitis (218, 223). The gene discussed is TNF; the disease is rheumatoid arthritis.